Elvinix Licenses Zealand GLP-1/Gastrin Peptide for Type 1 Diabetes

Delaware-based biopharmaceutical firm Elvinix Inc. has secured an exclusive worldwide license from Zealand Pharma A/S to commercialize a preclinical GLP-1/gastrin dual-agonist peptide platform, launching a new development effort to restore endogenous insulin production in Type 1 Diabetes (T1D). The Business Wire announcement marks a strategic shift toward regenerative peptide therapies that target functional beta-cell restoration rather than lifelong insulin replacement alone.

An estimated 9.5 million people worldwide live with Type 1 Diabetes, an autoimmune condition where immune-mediated destruction eliminates pancreatic beta cells. While modern management relies on exogenous insulin analogues and expanding GLP-1 receptor agonist formulations, no currently approved peptide therapy directly stimulates the regeneration of lost endocrine tissue while maintaining functional metabolic support.

Dual-Agonist Mechanism: Synergistic Beta-Cell Neogenesis

The licensed dual-agonist peptide platform combines GLP-1 receptor activation with targeted gastrin receptor stimulation. In pancreatic tissue, GLP-1 receptor signaling enhances glucose-dependent insulin secretion, improves beta-cell survival, and suppresses inappropriately elevated glucagon levels. Gastrin receptor stimulation acts primarily on ductal progenitor cells in the pancreas, signaling them to differentiate into new, functional insulin-producing beta cells.

Preclinical models developed by co-founder Dr. Alex Rabinovitch demonstrated that simultaneous stimulation of gastrin and GLP-1 pathways produces a synergistic increase in functional beta-cell mass exceeding what either single receptor agonist achieves alone. The dual-action peptide provides both the regenerative signal (gastrin) to generate new beta cells and the anti-apoptotic, metabolic support (GLP-1) to preserve newly formed cell clusters.

Disease Modification vs. Immune Suppression

The clinical rationale behind the GLP-1/gastrin dual peptide represents a distinct therapeutic philosophy in Type 1 Diabetes care. Existing disease-modifying interventions, such as the FDA-approved monoclonal antibody teplizumab (Tzield), focus on delaying T1D progression by modulating the autoimmune T-cell response. While immunosuppressants can preserve remaining beta-cell mass during early-stage disease, they do not regenerate tissue once significant beta-cell loss has occurred.

By focusing on direct tissue regeneration, Elvinix aims to restore sufficient endogenous insulin secretion to reduce glycemic variability, lower exogenous insulin requirements, and reduce long-term microvascular and macrovascular complications.

Regulatory and Scientific Leadership

Elvinix was co-founded by a prominent team of diabetes researchers and regulatory experts:

• Dr. Alex Rabinovitch, Emeritus Professor of Medicine at the University of Alberta, whose laboratory pioneered the dual gastrin/GLP-1 synergy concept in rodent and human islet models.
• Dr. Jay Skyler, Professor of Medicine, Pediatrics, and Psychology at the University of Miami Miller School of Medicine and former president of the American Diabetes Association.
• Dr. Alexander Fleming, former head of the FDA’s division responsible for metabolic and endocrine drug reviews, who brings regulatory insight to the clinical trial design process.

Chief Executive Officer Daniil Koshelev emphasized that acquiring Zealand Pharma’s established patent families and preclinical datasets provides a multi-year head start toward Investigational New Drug (IND) filing.

Strategic Repositioning in the Peptide Market

Zealand Pharma (Nasdaq Copenhagen: ZEAL) licensed out the dual-agonist asset as part of a ongoing portfolio optimization to focus clinical resources on its late-stage obesity pipeline, including petrelintide. As regulatory scrutiny around unapproved research peptides and compounding pharmacies intensifies—exemplified by recent FDA warning letters to compounding suppliers—pharmaceutical development of multi-target peptides continues to advance through structured clinical trials.

Elvinix plans to complete preclinical safety, formulation, and pharmacokinetic studies before initiating Phase 1 human trials in patients with Type 1 Diabetes. Not every late-stage program in this class is metabolic: the brenipatide GLP-1 addiction readout is a Phase 3 program in moderate-to-severe alcohol use disorder that has not yet reported, and no agent in this class is approved to treat addiction or depression.

---

PeptidesBeat is an independent editorial publication covering peptide policy, research, and industry developments. We do not sell peptides, recommend dosing, or provide medical advice. All content is informational. Peptides referenced may be subject to FDA restrictions; consult a licensed healthcare provider for any therapeutic question.